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Background. Maraviroc (MVC) is a candidate for human immunodeficiency virus (HIV) pre-exposure prophylaxis.
Methods. Phase 2 48-week safety/tolerability study was conducted, comparing 4 regimens: MVC alone, MVC plus emtricitabine
(FTC), MVC plus tenofovir disoproxil fumarate (TDF), and TDF plus FTC. Eligible participants were HIV-uninfected men and
transgender women reporting condomless anal intercourse with ≥1 HIV-infected or unknown-serostatus man within 90 days. At
each visit, assessments, laboratory testing, and counseling were done. Analyses were intention to treat.
Results. Among 406 participants, 84% completed follow-up, 7% stopped early, and 9% were lost to follow-up; 9% discontinued
their regimen early. The number discontinuing and the time to discontinuation did not differ among study regimens (P = .60). Rates
of grade 3–4 adverse events did not differ among regimens (P = .37). In a randomly selected subset, 77% demonstrated detectable
drug concentrations at week 48. Five participants acquired HIV infection (4 MVC alone, 1 MVC + TDF; overall annualized inci-
dence, 1.4% [95% confidence interval, .5%–3.3%], without differences by regimen; P = .32); 2 had undetectable drug concentrations
at every visit, 2 had low concentrations at the seroconversion visit, and 1 had variable concentrations.
Conclusions. MVC-containing regimens were safe and well tolerated compared with TDF + FTC; this study was not powered for
efficacy. Among those acquiring HIV infection, drug concentrations were absent, low, or variable. MVC-containing regimens may
warrant further study for pre-exposure prophylaxis.
Clinical Trials Registration. NCT01505114.
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New human immunodeficiency virus (HIV) infections contin-
ue to occur and disproportionately affect men who have sex
with men (MSM) [1]. HIV pre-exposure prophylaxis (PrEP)
with coformulated tenofovir disoproxil fumarate (TDF) plus
emtricitabine (FTC) was associated with a 44% reduction in
the rate of HIV acquisition in MSM in the iPrEx study [2]. Ran-
domized efficacy studies reported in 2015 demonstrated that
TDF + FTC was associated with an 86% reduction in HIV ac-
quisition in MSM when prescribed daily in the PROUD study
[3] or when taken on-demand in the intervention preventive de
l’exposition aux risque avec et pour les gays (IPERGAY) study
[4]. Current guidelines recommend daily oral HIV PrEP for
high-risk individuals [5, 6].
Although effective, in prior studies PrEP with TDF + FTC
was associated with gastrointestinal adverse effects in up to
18% of study participants [2, 7–9] and decreased renal function
in up to 18% [4, 10–12] and with a small, but statistically signifi-
cant, loss of bone mineral density [8, 13, 14]. In addition, drug
resistance developed in some participants with unsuspected
acute HIV infection randomized to TDF-based PrEP in the
iPrEx [2] and Partners PrEP studies [7, 15] and rarely, in on-
study participants in Partners PrEP [15].Given that TDF + FTC
is recommended among initial HIV treatment options [16, 17],
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increased drug resistance linked to the use of TDF + FTC PrEP
could compromise HIV treatment. Increased drug resistance
also could compromise the efficacy of TDF + FTC as PrEP
[18]. For these reasons, alternative PrEP regimens are needed.
Maraviroc (MVC) is a CCR5 antagonist HIV entry inhibitor
that was approved for treatment of HIV infection based on the
results of randomized clinical trials in HIV-infected, treatment-
experienced participants that demonstrated safety, tolerability,
and virologic efficacy [19]. MVC is active against R5 (CCR5-
tropic) HIV, which is associated with the majority of acute
HIV transmissions [20] and has several favorable properties
for an HIV PrEP agent; MVC is concentrated 8–26-fold higher
in the rectum compared with plasma [21]. It is prescribed infre-
quently for HIV treatment [16]. Preclinical efficacy of oral MVC
for HIV prevention was demonstrated in a humanized mouse
model [22], although other preclinical studies did not demon-
strate protection [23, 24]. MVC was generally safe in HIV-in-
fected individuals for ≥5 years without associated renal
toxicity [25] and was associated with less bone loss than TDF
in a comparative study of HIV-infected individuals [26]. Finally,
MVC was generally well tolerated in a 12-week pilot study of
HIV-uninfected participants with rheumatoid arthritis [27].
Based on these characteristics, we sought to study the safety
and tolerability of MVC-containing HIV PrEP regimens.
METHODS
Study Design and Participants
This was a prospective, randomized, double-blinded, multicen-
ter study of 4 antiretroviral regimens in at-risk, HIV-uninfected
men and transgender women who have sex with men. It was
conducted in the United States, sponsored by the Division of
AIDS (DAIDS) of the US National Institutes of Health through
the HIV Prevention Trials Network (HPTN), and cosponsored
by the AIDS Clinical Trials Group.
Eligible participants were born male, ≥18 years old, and self-
reported condomless anal intercourse with ≥1 man known to
be HIV-infected or of unknown HIV serostatus within 90
days before study entry. Eligible participants had adequate base-
line safety laboratory results, including a calculated creatinine
clearance ≥70 mL/min (Cockcroft-Gault), a nonreactive HIV
antibody test (tested at the site with the local standard-of-care
assay and subsequently confirmed at the HPTN Laboratory
Center with the ARCHITECT HIV Ag/Ab Combo [fourth-
generation assay], Abbott Laboratories), and a plasma HIV
RNA level below detection within 14 days of study entry. Par-
ticipants were excluded if they used any antiretroviral drug
within 90 days (eg, for PrEP or postexposure prophylaxis
[PEP]), reported active injection drug use, or had a reactive
HIV test or positive hepatitis B surface antigen. The study
was reviewed and approved by the institutional review boards
at each of the participating sites; all participants provided writ-
ten informed consent.
Randomization and Masking
Eligible participants were enrolled and randomly assigned with
equal probability to receive 1 of 4 antiretroviral regimens:
(1) MVC (Selzentry; ViiV Healthcare); (2) MVC plus FTC,
(Emtriva; Gilead Sciences); (3) MVC plus TDF (Viread; Gilead
Sciences); or (4) TDF plus FTC (control arm). Doses of the
study drugs were as follows: MVC, 300 mg; FTC, 200 mg; and
TDF, 300 mg; and the study regimen consisted of 3 pills, includ-
ing matching placebos, taken together orally once daily.
The computerized randomization method was developed,
implemented, and monitored by the Statistical Center for
HIV/AIDS Research and Prevention (Fred Hutchinson Cancer
Research Center, Seattle), and it was stratified by site using block
randomization with a block size of 12, such that approximately
equal numbers of participants were assigned to each arm within
each site. The site pharmacist received the randomized treat-
ment assignment. All other site staff and investigators were
blinded to the randomization assignments until completion of
follow-up.
Procedures
After enrollment and randomization, participants were seen at
weeks 2, 4, and 8 and then every 8 weeks through week 48. Study
drugs were discontinued at week 48, and a final visit was con-
ducted at week 49. At each visit, interval history, targeted phys-
ical examination, safety laboratory tests, blood plasma stored for
drug concentration measurements, adherence assessments,
risk-reduction counseling, condom distribution, and HIV test-
ing were conducted and study drugs were dispensed. Fasting
lipid levels were measured at baseline and at weeks 24 and 48.
Adherence support was provided at each visit through counsel-
or-guided discussions.
Testing for sexually transmitted infections (chlamydia and
gonorrhea nucleic acid testing of urine and rectal swab samples
and syphilis serology) was done at entry and weeks 16 or 24 and
40 or 48 and when an individual reported consistent symptoms;
participants were referred for treatment. Participants were eval-
uated at each visit for HIV exposure; those who requested PEP
for HIV exposure were referred locally. Participants who started
PEP were instructed to hold study medications and undergo re-
peated HIV testing ≥14 days after completing PEP; if HIV neg-
ative, they could resume their study regimen.
Quality assurance and specialized testing was performed at
the HPTN Laboratory Center in Baltimore, Maryland. This in-
cluded quality assurance testing for HIV and confirmation of
all HIV seroconversion events; HIV RNA testing was per-
formed retrospectively at the visit before HIV seroconversion
to determine whether participants had acute HIV infection at
that visit. Antiretroviral drug concentration testing was
performed on a random subset of plasma samples from
study participants (n = 160) collected at weeks 24 and 48.
MVC, FTC, and tenofovir (TFV) were quantified via validated
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liquid chromatographic–tandem mass spectrometric methods,
with assay limits of quantitation of 0.5 ng/mL for MVC and
0.3 ng/mL for FTC and TFV [28, 29]. Additional testing was
performed for participants with confirmed HIV seroconver-
sion; this included HIV RNA level, CD4 cell count, anti-
retroviral drug concentration testing, drug resistance
(PhenoSense GT; Monogram Biosciences), and viral tropism
testing (Trofile; Monogram Biosciences).
Drug Interaction Substudy
The first 72 participants (18 per study arm) who consented par-
ticipated in a substudy to evaluate drug interactions between
MVC, TFV, and FTC. These participants were reminded not
to take study medications the morning of their week 2 visit. Par-
ticipants had a blood sample collected before drug dosing
(steady-state trough concentration), underwent directly ob-
served study drug dosing, and then had another blood sample
drawn approximately 6 hours after the observed dose. MVC
concentrations in the MVC + FTC and MVC + TDF arms
were compared with those in the MVC-alone arm.
Outcomes
The primary outcome was safety and tolerability of the study
regimens. Safety was assessed by the investigators as the occur-
rence of grade 2 (moderate), 3 (severe), or 4 (life-threatening)
adverse events [30]. Tolerability was assessed as the proportion
of participants who permanently discontinued study drugs and
the time to permanent study drug discontinuation through 48
weeks of follow-up. Secondary outcomes included drug-drug
interactions and adherence assessed by detectable plasma
drug concentrations. Plasma drug concentrations were reported
as detectable above the limit of quantitation (all study drugs in
the regimen detected) or not. HIV testing was conducted at each
visit and whenever HIV infection was suspected; additional
testing was performed at the HPTN Laboratory Center to con-
firm cases of HIV infection.
Statistical Analysis
The planned enrollment was 400 participants (100 per arm)
with an assumed 5% loss-to-follow-up rate. The length of the
study was estimated at approximately 2 years, with 9 months
for accrual and 12-month follow-up of each participant. This
sample size was selected to provide sufficient power to detect
differences between arms for the tolerability end point (the
time to permanent discontinuation of study drugs), and to pro-
vide estimates for the true safety end point (occurrence of grade
3 or 4 or higher adverse events through 48 weeks). With the
sample of 100 participants per arm, if the true safety adverse
event rate was 20%, the estimate would have 95% confidence in-
tervals (CIs) of 12%–28%. The power to detect differences for
the tolerability end point was 72% for TDF + FTC versus each
of the 3 individual MVC-containing arms when the true hazard
ratio is 2.0 and the incidence rate is 30%.
Primary data analysis was performed for all enrolled partici-
pants on an intention-to-treat basis. Person-year analysis was
performed to summarize and compare the rates of grade 3 or
4 or higher adverse events between any 2 arms. Kaplan–Meier
estimates were calculated to summarize the distribution of per-
manent treatment discontinuation. Analyses of detectable study
drug concentrations were performed on a randomly selected
subset of week 24 and 48 plasma samples.
Summary statistics were calculated in proportions, means, or
event rates in person-years, depending on the variable being bi-
nary, continuous, or count, respectively. The χ2 test was used to
compare permanent study drug discontinuation rates, and the
log–rank test was used to compare times to permanent study
drug discontinuation between any 2 study arms and among
the 4 arms. HIV incidence was calculated using the exact meth-
od for Poisson counts. Differences were considered statistically
significant at P≤ .05. The study was reviewed biannually by an
independent study monitoring committee of the HPTN, and it
was registered at clinicaltrials.gov (NCT01505114).
RESULTS
A total of 406 participants were enrolled in the study between
July 2012 and April 2014 and randomized to 1 of 4 study reg-
imens (Figure 1); all but 2 started study drugs, 1 each random-
ized to MVC + FTC and MVC + TDF. The study population
was 100% male at birth, including 7 (2%) who self-identified
as female, transsexual, or transgender, with a median age of
30 years (Table 1). Study participants were 28% black, 22% La-
tino (of any race), and 62% white; 30% were younger than 26
years. Demographic characteristics were balanced between the
study arms. During screening, before enrollment, 31 (8%) of
the study participants had a total of 34 sexually transmitted in-
fections diagnosed: chlamydia in 15 (4%), gonorrhea in 5 (1%),
and syphilis in14 (3%).
Of 406 participants randomized, 343 (84%) completed study
follow-up, 28 (7%) stopped the study early, and 35 (9%) were
lost to follow-up (Figure 1). The most common reasons for in-
complete follow-up were inability to contact the participant
(9%) and participant choice to discontinue (3%). One partici-
pant died in an automobile accident. Thirty-six (9%) partici-
pants permanently discontinued the study regimen before
week 48; of these, 11 also terminated study participation, and
26 completed follow-up not taking study medications. There
was no difference among the study regimens in the proportion
of participants who permanently discontinued study drugs
(P = .60; Table 2) or in the time to permanent study drug dis-
continuation (P = .60; Table 2 and Figure 2). The most common
reasons for early discontinuation of the regimen early were par-
ticipant request (5%), clinical reasons determined by the inves-
tigator (1%), and reactive HIV antibody test(s) (1%; 4
participants). A fifth participant had a reactive HIV antibody
test at week 48 (the last visit while taking study medications).
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Among the 72 participants in the drug interaction substudy
at week 2, the predose (trough) MVC plasma concentrations did
not differ significantly among the MVC-alone, MVC + FTC,
and MVC + TDF arms in pairwise comparisons after Bonferro-
ni correction (all P > .05). There were no significant differences
in 6-hour postdose or 6-hour predose MVC concentrations
(P = .64 and .74, respectively). In a randomly selected subset
of 160 participants across the 4 study arms, detectable study
drug(s) were documented in 83% of plasma samples at week
24 and 77% at week 48, without significant differences among
the arms (week 24, P = .72; week 48, P = .39). Participants re-
ported at both 24 and 48 weeks that they took a median of
95% of their study medications as recommended, without dif-
ferences among the study arms.
Fifty-five participants experienced a total of 67 grade 3 or 4
adverse events; there was no difference among the 4 study reg-
imens in the occurrences or rates of these events (P = .37;
Table 2). Rates of selected gastrointestinal and renal grade
2–4 adverse events were also similar among the study regi-
mens (Table 2). Overall creatinine clearance decreased a me-
dian 4% from baseline to week 48, without differences among
the study arms (P = .60). During study follow-up, 89 partici-
pants (22%) had a total of 114 sexually transmitted infections
diagnosed: chlamydia in 48 (12%), gonorrhea in 42 (11%),
and syphilis in 24 (6%), without differences among the
study arms.
Five participants acquired HIV infection during the study:
4 randomized to MVC alone and 1 to MVC + TDF (Table 3).
Figure 1. Trial profile. Abbreviations: FTC, emtricitabine; MVC, maraviroc; TDF, tenofovir disoproxil fumarate.
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The overall annualized incidence of HIV was 1.4% (95%
CI,.5%–3.3%); HIV incidence in the individual study arms
was as follows: MVC alone, 4.5% (95% CI, 1.2%–11.6%);
MVC + FTC, 0% (0%–4.0%); MVC + TDF, 1.1% (0.003%–
6.0%); and TDF + FTC, 0% (0%–4.0%) (P = .32; Figure 3).
Four of these 5 participants had the wild-type CCR5 gene,
and 1 was heterozygous for the CCR5-Δ32 deletion. At the
visit when HIV seroconversion was documented, HIV RNA
levels ranged from 981 to 122 150 copies/mL, and CD4 cell
counts from 294 to 828 cells/mm3. All 5 participants had
R5 (CCR5-tropic) HIV without genotypic substitutions asso-
ciated with antiretroviral drug resistance; 1 of 5 of the viral
strains demonstrated modestly decreased phenotypic suscept-
ibility to nelfinavir (5-fold) and ritonavir (3-fold) owing to
polymorphisms. Of the 5 participants who acquired HIV in-
fection, 2 had undetectable plasma drug levels at every study
visit (1 randomized to MVC alone and 1 to MVC + TDF).
The 3 others, who were randomized to MVC alone, had
MVC levels of 0.7, 6.7, and 145 ng/mL at the seroconversion
visit (Figure 4). The expected predose, steady-state geometric
mean plasma concentration of MVC dosed at 300 mg/d is 32
ng/mL [31].
DISCUSSION
In this phase 2, prospective, randomized, double-blinded mul-
ticenter study, we showed that MVC-containing regimens were
generally safe and well tolerated compared with the control reg-
imen of TDF + FTC when assessed for use as HIV PrEP in a
population of at-risk men and transgender women who have
sex with men. The rates of grade 3/4 and specific adverse events
of interest, including gastrointestinal adverse effects, hypophos-
phatemia, and increased creatinine, were similar among the
study arms. It is critical that preventive medications be safe
and well tolerated with few attributable adverse effects. TDF is
a first-line drug for the treatment of HIV infection, whereas
MVC is infrequently used for treatment [16]. With demonstrat-
ed comparable safety and tolerability to the standard-of-care
regimen in the current study, MVC-containing regimens may
warrant further study as an alternative strategy for HIV PrEP.
Adherence is critical for HIV PrEP efficacy [32, 33]. The
iPrEx study reported 51% adherence in the subgroup of MSM
who did not acquire HIV infection during the study [2]. Nota-
bly, IPrEx was blinded, placebo controlled, and conducted at a
time when HIV PrEP was an unproven strategy, which could
Table 1. Baseline Characteristics of the Study Participants
Characteristic MVC (n = 101) MVC + FTC (n = 106) MVC + TDF (n = 99) TDF + FTC (n = 100) Total (N = 406)
Sex, born male, % 100 100 100 100 100
Age, median, y 30 29.5 30 31 30
Age range, y 18–65 18–62 18–70 18–60 18–70
Race, %a
American Indian/ Alaskan Native 4 4 1 3 3
Asian 5 1 4 5 4
Black 31 31 30 21 28
Pacific Islander 1 2 1 2 2
White 60 63 59 66 62
Other 11 9 8 11 10
Latino ethnicity, % 21 25 19 23 22
Marital status, %
Married/partnership 5 4 3 4 4
Living with primary partner 13 11 16 16 14
Not living with primary partner 6 14 14 7 10
Single, divorced, or widowed 76 71 67 72 71
Other 0 0 0 1 0
Employment status, %
Full-time 47 50 48 65 52
Part-time 21 23 29 18 23
Unemployed 33 26 22 17 25
Educational level, %
Less than high school 4 5 2 5 3
High school/trade school 22 15 14 13 17
Some college 36 28 42 38 36
Finished college 31 32 25 35 31
Advanced degree 8 20 16 9 13
Abbreviations: FTC, emtricitabine; MVC, maraviroc; TDF, tenofovir disoproxil fumarate.
a Participants could self-identify as >1 race.
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have adversely affected adherence. The more recent IPERGAY
study reported detectable plasma drug concentrations in 82%–
86% of the first 113 men enrolled and went on to demonstrate
86% efficacy in decreasing HIV infection [4]. In addition, of
note in the iPrEx [2] and IPERGAY [4] studies, men who had
more frequent condomless anal sex tended to be more adherent.
Table 2. Adverse Events
Event MVC (n = 101)
MVC + FTC
(n = 106)
MVC + TDF
(n = 99)
TDF + FTC
(n = 100)
Total
(N = 406) P Value
Permanent study drug discontinuations,
No. (%) of participants
7 (7) 9 (9) 12 (12) 8 (8) 36 (9) .60 (χ2 Test)
Time to permanent study drug
discontinuation, median (IQR), d
120 (74–263) 66 (42–222) 113 (42–260) 67 (34–141) 87 (45–210) .60 (Log–rank test)
Grade 3–4 adverse events, No. of
participants; No. of events
13; 15 11; 15 11; 14 20; 23 55; 67 .37 (Likelihood
ratio test)
Grade 3 events, No.
Related to study druga,b 2 2 4 9 17 . . .
Unrelated to study druga 11 10 7 13 41 . . .
Grade 4 events, No.
Related to study druga 0 0 0 0 0 . . .
Unrelated to study druga 2 3 3 1 9 . . .
Grade 3–4 adverse event rate, per
person-year (95% CI)
0.17 (0.09–0.28) 0.16 (0.09–0.27) 0.17 (0.09–0.28) 0.25 (0.16–0.38) 0.19 . . .
Selected adverse events (grade 2–4), %c
Diarrhea 3 8 7 4 5 . . .
Nausea 0 1 4 4 2 . . .
Vomiting 0 0 1 1 0.5 . . .
Unintentional weight loss 0 2 2 1 1 . . .
Hypophosphatemia 18 10 16 22 17 . . .
Increased creatinine 0 1 0 0 0.25 . . .
Abbreviations: CI, confidence interval; MVC, maraviroc; FTC, emtricitabine; IQR, interquartile range; TDF, tenofovir disoproxil fumarate.
a The study investigator assessed the relationship of adverse event to study drug.
b Grade 3 adverse events related to the study drug included the following: MVC, aspartate aminotransferase [AST] increase and hypophosphatemia; MVC + FTC, hyperlipidemia and
hypophosphatemia; MVC + TDF, AST increase, hypophosphatemia [2]; TDF + FTC, alanine aminotransferase increase [2], AST increase, hypersensitivity reaction, hypophosphatemia [4],
and neutrophil count decreased.
c All events listed are grade 2 with the exception of hypophosphatemia, which included 2 grade 3 events.
Figure 2. Time to permanent study discontinuation and shown by Kaplan–Meier plot. Abbreviations: FTC, emtricitabine; MVC, maraviroc; TDF, tenofovir disoproxil fumarate.
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In our study conducted at a time when HIV PrEP was known to
significantly reduce the risk of HIV infection, our at-risk partic-
ipants had study drugs detected in >75% of plasma samples
tested, suggesting high adherence, although simply detecting
antiretroviral drugs is not the same as documenting target
drug concentrations.
Prior drug interaction studies conducted in HIV-uninfected
volunteers demonstrated the lack of effects of MVC on the
pharmacokinetics of nucleoside reverse-transcriptase inhibi-
tors, including zidovudine, lamivudine, and TFV [34]. There
were no available data on the interaction of MVC and FTC.
We confirmed that there were no significant interactions be-
tween MVC and TDF or between MVC and FTC.
Prior preclinical studies explored MVC for prevention of
HIV acquisition, and found variable outcomes. Neff et al [22]
used a humanized mouse model given MVC orally daily for
7 days with a vaginal HIV challenge on day 4 and reported pro-
tection against HIV infection. In contrast, Massud et al [23]
used a macaque model given an oral MVC dose 24 hours before
rectal exposure and found that 5 of 6 animals acquired simian/
human immunodeficiency virus infection by the fifth rectal
challenge despite achieving target drug levels. Of note, MVC
disassociates 10 times more rapidly from the macaque CCR5 re-
ceptor compared with the human CCR5 receptor [35]. Coll et al
[24] tested single-dose MVC in human subjects and assessed
HIV infectability ex vivo using a rectal tissue explant model,
and found a minimal reduction in HIV infection. The investi-
gators attributed this to the loss of approximately 60% of MVC
from the biopsy tissue into the culture medium in the first hour
and of >90% loss of MVC following overnight incubation.
These data suggest that animal and ex vivo models may
Table 3. HIV Infections
Participant
Age,
y
HIV Risk
Group
Race/
Ethnicity Study Arm
1st Reactive
HIV Test,
Study wk
HIV RNA,
Copies/ mL
HIV
Tropism
Genotypic
Drug
Resistance
CD4 Cell
Count, Cells/
mm3/%
Study Drug
Concentration at
Seroconversion
Study Visit, ng/mLa
1 20 MSM Black MVC + TDF 9 122 150 R5 None 357/25 MVC: 0; TFV: 0
2 61 MSM Asian MVC 16 981 R5 Noneb 294/20 MVC: 145
3 21 MSM Mixed
race
MVC 28 106 240 R5 None 325/23 MVC: 0
4 35 MSM White MVC 38 13 626 R5 None 828/38 MVC: 6.7
5 36 MSM Black MVC 48 52 191 R5 None 804/40 MVC: 0.7
Abbreviations: HIV, human immunodeficiency virus; MSM, men who have sex with men; MVC, maraviroc; TDF, tenofovir disoproxil fumarate; TFV, tenofovir.
a Concentrations were reported as detectable or not detectable with the following limits of detection: MVC, 0.5 ng/mL; FTC and TFV, 0.3 ng/mL. The expected predose, steady-state geometric
mean concentration with MVC dosed at 300 mg/d is 32 ng/mL [31].
b Participant 2 was infected with a viral strain that demonstrated 5- and 3-fold reduced phenotypic susceptibility to the HIV protease inhibitors nelfinavir and ritonavir, respectively; all other
participants had no reduced phenotypic susceptibility.
Figure 3. Estimated incidence of human immunodeficiency virus (HIV) infection
by study arm, calculated using the exact method for Poisson counts. The overall HIV
incidence was 1.4% (95% confidence interval [CI], .5%–3.3%), without differences
among the study arms (P = .32). Abbreviations: FTC, emtricitabine; MVC, maraviroc;
TDF, tenofovir disoproxil fumarate.
Figure 4. Study drug plasma concentrations over time in participants experienc-
ing human immunodeficiency virus (HIV) seroconversion. Each line presents data
from a unique participant who acquired HIV infection and had detectable study
drug plasma concentrations; all 3 were randomized to the maraviroc (MVC)–alone
arm. Note: 2 other participants who acquired HIV infection, 1 randomized to MVC
and 1 to MVC plus tenofovir disoproxil fumarate, had undetectable study drug con-
centrations at every study visit and are not shown. Diamond points represent study
visits at which HIV seroconversion was documented. Boxed points represent visits at
which HIV RNA was detected retrospectively; HIV antibody test results at that visit
were negative or nonreactive. The expected predose, steady-state geometric mean
concentration with MVC dosed at 300 mg/d is 32 ng/mL [31].
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have limitations in predicting the clinical efficacy of MVC-
containing regimens for HIV PrEP.
Five study participants acquired HIV infection during our
study: 4 randomized to MVC alone and 1 to MVC + TDF. All
had R5 (CCR5-tropic) HIV, without evidence of X4 (CXCR4-
tropic) virus, and no participant demonstrated drug resistance
as assessed with conventional genotypic testing. Notably, 2 of
the 5 participants who acquired HIV infection had no detect-
able study drugs at any visit, and 2 others had MVC plasma
concentrations below the expected steady-state concentration
at HIV seroconversion. The single participant with an expected
MVC concentration documented at the seroconversion visit
had concentrations consistent with less than daily dosing for
half of his visits, suggesting inconsistent adherence. The similar
distribution of new sexually transmitted infections among the
study arms suggests that sexual behavior did not differ among
the groups. Our phase 2 study was not designed to detect a dif-
ference in HIV incidence among the study arms, and no defin-
itive conclusions about comparative efficacy can be made.
There are strengths and limitations of this study. As a pro-
spective, randomized, double-blinded study conducted pre-
dominately in at-risk MSM in the United States who were
young and racially and ethnically diverse, the results are prob-
ably generalizable to one of the populations most in need of
HIV PrEP. The active-controlled design ensured that every par-
ticipant received an antiretroviral drug regimen (ie, there was no
all-placebo arm). Frequent follow-up allowed ongoing risk-
reduction counseling, adherence support, and testing for HIV
and other sexually transmitted infections, which may have pro-
moted adherence. Detection rates of the study medications in
plasma were high. Study limitations include the study popula-
tion who were “at-risk” rather than “high risk” based on self-re-
ported behavior, potentially limiting generalizability. Nearly
80% were highly educated and may have been better informed
than prior clinical trial participants about HIV PrEP and per-
haps more adherent than prior clinical trials participants. We
enrolled few transgender women, limiting our ability to make
conclusions for this important at-risk population. The study
regimen consisted of 3 pills (2 more than the standard 1-pill
TDF + FTC PrEP regimen) and used daily dosing of MVC, al-
though the drug is approved for HIV treatment with twice-daily
dosing. Finally, our study was not powered to detect differences
in specific adverse events and had limited follow-up.
In summary, we found that MVC-containing HIV PrEP reg-
imens were generally safe and well tolerated compared with the
standard-of-care TDF + FTC HIV PrEP regimen. All regimens
were associated with high rates of study drug detection in plas-
ma, suggesting our participants were adherent. Although no de-
finitive conclusions about efficacy can be drawn from the current
study, the overall annualized HIV incidence rate was low at 1.4%,
and did not differ significantly among the 4 study arms (P = .32).
Although HIV PrEP regimens containing long-acting injectable
antiretrovirals or intravenous monoclonal antibodies are under
investigation, these regimens may not be ideal for everyone
given individual preferences, agent-specific toxic effects, the re-
quirements for repeated and consistent parenteral administra-
tion, and the challenges in managing prolonged drug
concentrations. Combination MVC-containing oral PrEP regi-
mens may warrant further investigation in fully powered efficacy
studies as an alternative to TDF + FTC HIV PrEP.
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